<DOC>
	<DOC>NCT02193217</DOC>
	<brief_summary>The purpose of this study is to explore the cardiac pharmacodynamics, safety and tolerability of MT-1303 in healthy subjects.</brief_summary>
	<brief_title>A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Healthy and free from clinically significant illness or disease. Male and female subjects of nonchildbearing potential aged 18 to 55 years. Normal or nonclinically significant 12lead ECG. Holter recording with no clinically significant abnormalities. Systolic blood pressure: 90 to 140 mmHg, diastolic blood pressure: 50 to 90 mmHg A History of severe adverse reaction or allergy to any medical product. Clinically significant endocrine, thyroid, hepatic, respiratory, gastrointestinal, renal, cardiovascular disease, eye disorder or history of psychiatric/psychotic disorder. A history of tuberculosis. Have a positive HBsAg, HBcAb, HCVAb or HIV1 and HIV2 test. Previously having received MT1303, fingolimod, or any other sphingosine1phosphate receptor modulators. Clinical relevant abnormal medical history, or physical findings or laboratory values. Clinically significant 12lead ECG abnormalities. Clinical relevant abnormal findings in echocardiograph.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>